Email Alert RSS
Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
PAN Xiaojun, CHEN Dechang. Gut Microbiota in Hemodynamics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 936-941. DOI: 10.12290/xhyxzz.2022-0468
Citation: PAN Xiaojun, CHEN Dechang. Gut Microbiota in Hemodynamics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 936-941. DOI: 10.12290/xhyxzz.2022-0468
shu

Gut Microbiota in Hemodynamics

  • Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Funds: 

National Natural Science Foundation of China 81873944

National Natural Science Foundation of China 82172152

Shanghai Science and Technology Commission 20DZ2200500

More Information
  • Corresponding author:

    CHEN Dechang, E-mail: cdc12064@rjh.com.cn

  • Received Date: August 23, 2022
  • Accepted Date: October 19, 2022
  • Available Online: October 26, 2022
  • Issue Publish Date: November 29, 2022
    Graphical Abstract
    • Abstract
  • The gut microbiota is a powerful "organ" composed of prokaryotic organisms (bacteria), eukaryotic microorganisms (including fungi and protozoa) and viruses, which plays a crucial role in the nutrition metabolism, maintenance of the integrity of intestinal mucosal barrier, and immune regulation of the body. Researches have shown that intestinal microecology is related to the pathogenesis of many diseases, such as neuropsychiatric diseases, autoimmune diseases, cancer and chronic metabolic diseases. Recent studies have found that gut microbiota can regulate hemodynamics through the oxidation of trimethylamine and short chain fatty acids. At the same time, gut microbiota disorder and translocation can activate the body's inflammatory response, affecting the stability of the body's hemodynamics.In this article, we summarize the relationship between gut microbiota and hemodymamics, in order to provide reference for further research.
    • FullText(HTML)
    • References (59)
  • [1]
    Socała K, Doboszewska U, Szopa A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders[J]. Pharmacol Res, 2021, 172: 105840. DOI: 10.1016/j.phrs.2021.105840
    [2]
    Xiao L, Liu Q, Luo M, et al. Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome[J]. Front Cell Infect Microbiol, 2021, 11: 729346. DOI: 10.3389/fcimb.2021.729346
    [3]
    Doroszkiewicz J, Groblewska M, Mroczko B. The Role of Gut Microbiota and Gut-Brain Interplay in Selected Diseases of the Central Nervous System[J]. Int J Mol Sci, 2021, 22: 10028. DOI: 10.3390/ijms221810028
    [4]
    Hou H, Chen D, Zhang K, et al. Gut microbiota-derived short-chain fatty acids and colorectal cancer: Ready for clinical translation?[J]. Cancer Lett, 2022, 526: 225-235. DOI: 10.1016/j.canlet.2021.11.027
    [5]
    Zaky A, Glastras SJ, Wong MYW, et al. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease[J]. Int J Mol Sci, 2021, 22: 9641. DOI: 10.3390/ijms22179641
    [6]
    Cai J, Sun L, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumori-genesis[J]. Cell Host Microbe, 2022, 30: 289-300. DOI: 10.1016/j.chom.2022.02.004
    [7]
    Adhikari AA, Ramachandran D, Chaudhari SN, et al. A Gut-Restricted Lithocholic Acid Analog as an Inhibitor of Gut Bacterial Bile Salt Hydrolases[J]. ACS Chem Biol, 2021, 16: 1401-1412. DOI: 10.1021/acschembio.1c00192
    [8]
    Campbell C, McKenney PT, Konstantinovsky D, et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells[J]. Nature, 2020, 581: 475-479. DOI: 10.1038/s41586-020-2193-0
    [9]
    Jin WB, Li TT, Huo D, et al. Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome[J]. Cell, 2022, 185: 547-562. e522. DOI: 10.1016/j.cell.2021.12.035
    [10]
    Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease[J]. Nat Microbiol, 2019, 4: 293-305. DOI: 10.1038/s41564-018-0306-4
    [11]
    Gadaleta RM, Garcia-Irigoyen O, Cariello M, et al. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor[J]. EBioMedicine, 2020, 54: 102719. DOI: 10.1016/j.ebiom.2020.102719
    [12]
    Doden HL, Wolf PG, Gaskins HR, et al. Completion of the gut microbial epi-bile acid pathway[J]. Gut Microbes, 2021, 13: 1-20.
    [13]
    Turner JR. Intestinal mucosal barrier function in health and disease[J]. Nat Rev Immunol, 2009, 9: 799-809. DOI: 10.1038/nri2653
    [14]
    Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure[J]. Nat Rev Cardiol, 2019, 16: 137-154. DOI: 10.1038/s41569-018-0108-7
    [15]
    Rajilić-Stojanović M, de Vos WM. The first 1000 cultured species of the human gastrointestinal microbiota[J]. FEMS Microbiol Rev, 2014, 38: 996-1047. DOI: 10.1111/1574-6976.12075
    [16]
    Kamada N, Seo SU, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease[J]. Nat Rev Immunol, 2013, 13: 321-335. DOI: 10.1038/nri3430
    [17]
    Stanley EG, Bailey NJ, Bollard ME, et al. Sexual dimorphism in urinary metabolite profiles of Han Wistar rats revealed by nuclear-magnetic-resonance-based metabonomics[J]. Anal Biochem, 2005, 343: 195-202. DOI: 10.1016/j.ab.2005.01.024
    [18]
    Tang WHW, Bäckhed F, Landmesser U, et al. Intestinal Microbiota in Cardiovascular Health and Disease: JACC State-of-the-Art Review[J]. J Am Coll Cardiol, 2019, 73: 2089-2105.
    [19]
    Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J]. Nature, 2011, 472: 57-63. DOI: 10.1038/nature09922
    [20]
    Zhu W, Buffa JA, Wang Z, et al. Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethyla-mine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk[J]. J Thromb Haemost, 2018, 16: 1857-1872. DOI: 10.1111/jth.14234
    [21]
    Bergeron N, Williams PT, Lamendella R, et al. Diets high in resistant starch increase plasma levels of trimethylamine-N-oxide, a gut microbiome metabolite associated with CVD risk[J]. Br J Nutr, 2016, 116: 2020-2029. DOI: 10.1017/S0007114516004165
    [22]
    Hauet T, Baumert H, Gibelin H, et al. Noninvasive monitoring of citrate, acetate, lactate, and renal medullary osmolyte excretion in urine as biomarkers of exposure to ischemic reperfusion injury[J]. Cryobiology, 2000, 41: 280-291. DOI: 10.1006/cryo.2000.2291
    [23]
    Griffin JL, Wang X, Stanley E. Does our gut microbiome predict cardiovascular risk? A review of the evidence from metabolomics[J]. Circ Cardiovasc Genet, 2015, 8: 187-191. DOI: 10.1161/CIRCGENETICS.114.000219
    [24]
    Seldin MM, Meng Y, Qi H, et al. Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB[J]. J Am Heart Assoc, 2016, 5.
    [25]
    Makrecka-Kuka M, Volska K, Antone U, et al. Trimethylamine N-oxide impairs pyruvate and fatty acid oxidation in cardiac mitochondria[J]. Toxicol Lett, 2017, 267: 32-38. DOI: 10.1016/j.toxlet.2016.12.017
    [26]
    Savi M, Bocchi L, Bresciani L, et al. Trimethylamine-N-Oxide (TMAO)-Induced Impairment of Cardiomyocyte Function and the Protective Role of Urolithin B-Glucuronide[J]. Molecules, 2018, 23.
    [27]
    Jacobs J, Braun J. Host genes and their effect on the intestinal microbiome garden[J]. Genome Med, 2014, 6: 119. DOI: 10.1186/s13073-014-0119-x
    [28]
    Moron R, Galvez J, Colmenero M, et al. The Importance of the Microbiome in Critically Ⅲ Patients: Role of Nutrition[J]. Nutrients, 2019, 11.
    [29]
    Valdés-Duque BE, Giraldo-Giraldo NA, Jaillier-Ramírez AM, et al. Stool Short-Chain Fatty Acids in Critically Ⅲ Patients with Sepsis[J]. J Am Coll Nutr, 2020, 39: 706-712. DOI: 10.1080/07315724.2020.1727379
    [30]
    Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation[J]. Nature, 2013, 504: 451-455. DOI: 10.1038/nature12726
    [31]
    Pluznick J. A novel SCFA receptor, the microbiota, and blood pressure regulation[J]. Gut Microbes, 2014, 5: 202-207. DOI: 10.4161/gmic.27492
    [32]
    Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation[J]. Proc Natl Acad Sci U S A, 2013, 110: 4410-4415. DOI: 10.1073/pnas.1215927110
    [33]
    Samuel BS, Shaito A, Motoike T, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41[J]. Proc Natl Acad Sci U S A, 2008, 105: 16767-16772. DOI: 10.1073/pnas.0808567105
    [34]
    Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43[J]. Nature, 2009, 461: 1282-1286. DOI: 10.1038/nature08530
    [35]
    Le Poul E, Loison C, Struyf S, et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation[J]. J Biol Chem, 2003, 278: 25481-25489. DOI: 10.1074/jbc.M301403200
    [36]
    Tazoe H, Otomo Y, Karaki S, et al. Expression of short-chain fatty acid receptor GPR41 in the human colon[J]. Biomed Res, 2009, 30: 149-156. DOI: 10.2220/biomedres.30.149
    [37]
    Samuel BS, Gordon JI. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism[J]. Proc Natl Acad Sci U S A, 2006, 103: 10011-10016. DOI: 10.1073/pnas.0602187103
    [38]
    Durazzi F, Sala C, Castellani G, et al. Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota[J]. Sci Rep, 2021, 11: 3030. DOI: 10.1038/s41598-021-82726-y
    [39]
    Osuka A, Shimizu K, Ogura H, et al. Prognostic impact of fecal pH in critically ill patients[J]. Crit Care, 2012, 16: R119. DOI: 10.1186/cc11413
    [40]
    Yamada T, Shimizu K, Ogura H, et al. Rapid and Sustained Long-Term Decrease of Fecal Short-Chain Fatty Acids in Critically Ill Patients With Systemic Inflammatory Response Syndrome[J]. JPEN J Parenter Enteral Nutr, 2015, 39: 569-577. DOI: 10.1177/0148607114529596
    [41]
    Ladopoulos T, Giannaki M, Alexopoulou C, et al. Gastrointestinal dysmotility in critically ill patients[J]. Ann Gastroenterol, 2018, 31: 273-281.
    [42]
    Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome[J]. Gut, 2016, 65: 740-748. DOI: 10.1136/gutjnl-2015-310376
    [43]
    Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome[J]. Clin Microbiol Infect, 2016, 22: 178. e171-e178. e179.
    [44]
    Habes QLM, van Ede L, Gerretsen J, et al. Norepinephrine Contributes to Enterocyte Damage in Septic Shock Patients: A Prospective Cohort Study[J]. Shock, 2018, 49: 137-143. DOI: 10.1097/SHK.0000000000000955
    [45]
    Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness[J]. Curr Opin Crit Care, 2003, 9: 143-151. DOI: 10.1097/00075198-200304000-00011
    [46]
    De-Souza DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: effect of gluta-mine[J]. Crit Care Med, 2005, 33: 1125-1135. DOI: 10.1097/01.CCM.0000162680.52397.97
    [47]
    Wang C, Li Q, Ren J. Microbiota-Immune Interaction in the Pathogenesis of Gut-Derived Infection[J]. Front Immunol, 2019, 10: 1873. DOI: 10.3389/fimmu.2019.01873
    [48]
    Andriamihaja M, Lan A, Beaumont M, et al. The deleteri-ous metabolic and genotoxic effects of the bacterial metabolite p-cresol on colonic epithelial cells[J]. Free Radic Biol Med, 2015, 85: 219-227. DOI: 10.1016/j.freeradbiomed.2015.04.004
    [49]
    Simonen M, Dali-Youcef N, Kaminska D, et al. Conjugated bile acids associate with altered rates of glucose and lipid oxidation after Roux-en-Y gastric bypass[J]. Obes Surg, 2012, 22: 1473-1480. DOI: 10.1007/s11695-012-0673-5
    [50]
    le Roux CW, Bloom SR. Why do patients lose weight after Roux-en-Y gastric bypass?[J]. J Clin Endocrinol Metab, 2005, 90: 591-592. DOI: 10.1210/jc.2004-2211
    [51]
    Ince C, Mayeux PR, Nguyen T, et al. The Endothelium in Sepsis[J]. Shock, 2016, 45: 259-270. DOI: 10.1097/SHK.0000000000000473
    [52]
    Kakihana Y, Ito T, Nakahara M, et al. Sepsis-induced myocardial dysfunction: pathophysiology and management[J]. J Intensive Care, 2016, 4: 22. DOI: 10.1186/s40560-016-0148-1
    [53]
    Hollenberg SM. Understanding stress cardiomyopathy[J]. Intensive Care Med, 2016, 42: 432-435. DOI: 10.1007/s00134-015-4018-4
    [54]
    Stanzani G, Duchen MR, Singer M. The role of mitochondria in sepsis-induced cardiomyopathy[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865: 759-773. DOI: 10.1016/j.bbadis.2018.10.011
    [55]
    Yin J, Liao SX, He Y, et al. Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack[J]. J Am Heart Assoc, 2015, 4: e002699. DOI: 10.1161/JAHA.115.002699
    [56]
    Wang F, Li Q, Wang C, et al. Dynamic alteration of the colonic microbiota in intestinal ischemia-reperfusion injury[J]. PLoS One, 2012, 7: e42027. DOI: 10.1371/journal.pone.0042027
    [57]
    Nagatomo Y, Tang WH. Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis[J]. J Card Fail, 2015, 21: 973-980. DOI: 10.1016/j.cardfail.2015.09.017
    [58]
    Harikrishnan S. Diet, the Gut Microbiome and Heart Failure[J]. Card Fail Rev, 2019, 5: 119-122. DOI: 10.15420/cfr.2018.39.2
    [59]
    Wozniak H, Beckmann TS, Fröhlich L, et al. The central and biodynamic role of gut microbiota in critically ill patients[J]. Crit Care, 2022, 26: 250. DOI: 10.1186/s13054-022-04127-5
    • Related Articles

  • Related Articles

    [1]SONG Tianjiao, WANG Xiaoting, CHAO Yangong. Particle Multimodality Monitoring and Hemodynamics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 942-947. DOI: 10.12290/xhyxzz.2022-0626
    [2]WANG Guangjian, WANG Xiaoting. Host Response and Hemodynamics[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 929-935. DOI: 10.12290/xhyxzz.2022-0483
    [3]Wan-hong YIN, Yan KANG. Hemodynamic Therapy for COVID-19 Patients with Acute Respiratory Distress Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 518-521. DOI: 10.3969/j.issn.1674-9081.2020.05.004
    [4]Zhi-qun XING, Xiao-ting WANG, Da-wei LIU. Critical Ultrasonography: Hemodynamic Helper[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 461-464. DOI: 10.3969/j.issn.1674-9081.2019.05.007
    [5]Li LI, Jing YAN. Dramatic Changes in Hemodynamics from the Changes of Surviving Sepsis Campaign Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 446-449. DOI: 10.3969/j.issn.1674-9081.2019.05.004
    [6]Da-wei LIU. Thirty Years of Clinical Hemodynamics[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 433-437. DOI: 10.3969/j.issn.1674-9081.2019.05.001
    [7]Ran ZHU, Xiao-ting WANG, Xiao-chun MA. From Cognition to Management: Interpretation of Experts Consensus on the Management of the Right Heart Function in Critically Ill Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 407-410. DOI: 10.3969/j.issn.1674-9081.2018.05.006
    [8]Jia-yu MAO, Xiao-ting WANG, Da-wei LIU. Importance of Critical Ultrasonography to Comprehensive Etiologic Management in Critical Care Medicine[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(5): 404-406. DOI: 10.3969/j.issn.1674-9081.2018.05.005
    [9]Rong-li YANG, Xiu-kai CHEN, Xiao-ting WANG, Da-wei LIU. Critical Care Blood Purification and Integration[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(6): 375-380. DOI: 10.3969/j.issn.1674-9081.2017.06.011
    [10]Da-wei LIU. Shock: the Revelation from Critical Hemodynamic Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(6): 322-325. DOI: 10.3969/j.issn.1674-9081.2017.06.001

  • Cited by

    Periodical cited type(4)

    1. 黄念文，李海松，王彬，王伊光，冯隽龙，孙龙吉，王继升. 基于肠道菌群探讨活血化瘀法治疗勃起功能障碍. 中医学报. 2024(05): 924-928 .
    2. 刘喆雯，陈其华. 基于肠道菌群从“土郁夺之”论治慢性前列腺炎. 中国中医药信息杂志. 2024(05): 15-20 .
    3. 陈瑞泽，李瑞仕，郭峰，王泽坤. 基于肠道微生态探讨推拿治疗孤独症谱系障碍的思路. 江西中医药. 2024(09): 76-80 .
    4. 黄念文，王彬，王继升，赵琦，冯隽龙，孙龙吉，李海松. 论肠道菌群是补肾活血法治疗慢性前列腺炎的重要靶点. 湖南中医药大学学报. 2023(03): 565-570 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2649) PDF downloads (120) Cited by(5)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close